04 March 2019
ADAMAS FINANCE ASIA LIMITED
("ADAM" or the "Company")
Admission of Shares
Further to the announcement of 25th February 2019, the Company confirms that the 159,847 ordinary shares shares issued to minority shareholder (the "Vendor") of Hong Kong Mining Holdings Limited ("HKMH") (the "Vendor Shares") will be admitted to trading on AIM on 4th March 2019.
The Company's total issued share capital will then comprise 88,733,069 Ordinary Shares, including 730,529 Ordinary Shares held in treasury. This figure of 88,733,069 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
Adamas Finance Asia Limited
+44 (0) 1825 830587
WH Ireland Limited - Nominated Adviser
James Sinclair Ford
+44 (0) 20 7220 1666
VSA Capital Limited - Corporate Broker
+44 (0) 20 3005 5000
| || |
Buchanan - Financial PR
+44 (0) 20 7466 5000
About Adamas Finance Asia
ADAM is a London quoted investment company focusing on delivering long-term income and capital growth to shareholders through a diverse portfolio of pan-Asian investments. It aims to provide uncorrelated returns through a combination of capital growth and dividend income from a broad spectrum of national geographies and asset classes from the Asian Small and Medium Enterprise (SME) sector.
The company's investment manager, Harmony Capital, which has a dedicated team with real Asian expertise, is focussed on the strategy of creating income and capital growth. Harmony is sourcing predominately private opportunities and has created a strong pipeline of income generating assets from potential investments in industries such as healthcare, fintech, hospitality, IT and property across Asia.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.